Position of the Transparency Council – Keytruda (pembrolizumab)
At its meeting on 25 May 2025, the Transparency Council adopted position No. 64/2025 on the appraisal of drug Keytruda (pembrolizumab) under drug program B.159. “Treatment of patients with cervical cancer (ICD-10: C53)”